Get the Stockscreener App
24.29
2.62%
0.62
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.29, with a volume of 58.90M.
It is up +2.62% in the last 24 hours and down -6.03% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$23.67
Open:
$23.74
24h Volume:
58.90M
Relative Volume:
1.54
Market Cap:
$138.44B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
18.62
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-3.65%
1M Performance:
-6.03%
6M Performance:
-3.19%
1Y Performance:
+0.21%
1-Day Range:
$23.74
$24.35
1-Week Range:
$23.62
$25.30
52-Week Range:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.29 | 138.44B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,208.12 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.66 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.41 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock? - The Motley Fool
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now - Yahoo Finance
Is Pfizer (NYSE:PFE) Building A Stronger Cancer Portfolio? - Kalkine Media
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends - Yahoo Finance
Pfizer (PFE) Wins EU Approval For Keytruda And Padcev In Bladder Cancer - simplywall.st
Pfizer Beats Ex-Worker's Whistleblower Retaliation Suit - Law360
Prevnar 20 from Pfizer Inc.broader pneumococcal cover in one syringe - Ad-hoc-news.de
Pfizer Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Price to earnings forward of Pfizer Inc. – BCS:PFECL - TradingView
Why Did Pfizer (NYSE:PFE) Gain Attention After FDA Approval? - Kalkine Media
Pfizer: Why Being Bullish Makes Sense Despite The Patent Cliff (NYSE:PFE) - Seeking Alpha
Nike Names Pfizer’s Denton as Next CFO - WSJ
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? - 24/7 Wall St.
Vitiligo Market to Witness Transformational Growth Opportunities by 2034 – DelveInsight | Pfizer, Clinuvel, Inc., Clinuvel Pharma, Bioniz Therapeutics, TAGCyx Biotech - Barchart.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Dividend Roundup: Pfizer, AT&T, Comcast, Sysco, and more - Seeking Alpha
Pfizer (PFE) Wins New IBRANCE Use As Lung Cancer Trial Tests Its Pipeline - simplywall.st
Pfizer reaffirmed 2026 guidance after CFO exit, shares trade near recent lows - Ad-hoc-news.de
Price to sales forward of Pfizer, Inc. – NYSE:PFE - TradingView
Pfizer Inc Shs Unsponsored Brazilian Depository Receipts Repr 0.25 Sh Actuals & Estimates (BMFBOVESPA:PFIZ34) - TradingView
Pfizer stock under pressure near yearly lows despite launch of new obesity study programs - Traders Union
Price to earnings forward of Pfizer Inc. – TRADEGATE:PFE - TradingView
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
Pfizer Inc. Actuals & Estimates (BVC:PFE) - TradingView
Pfizer Inc. stock underperforms Thursday when compared to competitors - MarketWatch
PFE Stock Quote Price and Forecast - CNN
Antibody-Drug Conjugates: Not Quite Worked Out Yet (PFE) - Seeking Alpha
Enterprise value to revenue forward of Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs – BCBA:PFE.B - TradingView
FDA expands Pfizer's Ibrance label for frontline maintenance in advanced breast cancer - MSN
Price to earnings forward of Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs – BCBA:PFE.B - TradingView
Pfizer’s US Paxlovid patent fight turns on a single error - Life Sciences Intellectual Property Review
Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside - Bloomberg
FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer - Benzinga
Enterprise value to EBITDA forward of Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs – BCBA:PFE.B - TradingView
Pfizer Declares Third-Quarter 2026 Dividend - BioSpace
ANTITRUST—D. Conn.: Pfizer off the... - VitalLaw.com
Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative - Yahoo Finance
PATENT—Fed. Cir.: Pfizer Inc. prevails in coronavirus-treatment patent dispute with biotechnology company - VitalLaw.com
Pfizer Ducks Generic Drug Claims From State AGs - Law360
Nike Hires Pfizer’s Denton to Take Over for Departing CFO - The Business of Fashion
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Nike lands Pfizer CFO with $7.3M ‘new hire’ cash award - CFO Dive
Pfizer declares $0.43 quarterly dividend for third quarter By Investing.com - Investing.com Canada
Pfizer Keeps Quarterly Dividend at $0.43 per Share, Payable Sept. 1, to Shareholders of Record July 24 - marketscreener.com
Pfizer Inc. Declares Quarterly Dividend for Third-Quarter of 2026, Payable on September 1, 2026 - marketscreener.com
Pfizer (PFE) Reaffirms FY 2026 Outlook Amid Leadership Change - Insider Monkey
Pfizer Inc. (PFE) Stock: FDA Clears IBRANCE for HER2+ Breast Cancer - parameter.io
Pfizer Dismissed From US States' Lawsuit on Generic Drug Price Fixing - marketscreener.com
Pfizer Inc Stock (PFE) Moved Down by 3.16% on Jun 24: A Full Analysis - TradingKey
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance - Business Wire
Pfizer Freed From US States’ Drug Price-Fixing Conspiracy Claims - Bloomberg Law News
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):